The study of a tumor’s immune repertoire includes an analysis of T cell receptors and B cell receptors that allow an immune system to adapt to changes and launch an immune system response. Understanding the immune repertoire of pediatric tumors could lead to advancements in immunotherapy, a therapy that uses a patient’s own immune system to attack a tumor. Researchers will analyze data from pediatric brain tumors through access to the Pediatric Brain Tumor Atlas in a search for relevant features of the immune system that could be utilized in new immunotherapies.
What are the goals of this project?
Researchers are looking to better understand the immune system of pediatric brain tumors through an analysis of T cell and B cell receptors.
What is the impact of this project?
An in-depth understanding of a tumor’s immune repertoire could guide researchers in developing treatments such as new immunotherapies.
Why is the CBTN request important to this project?
The broad set of data across pediatric brain tumor types provided through the Pediatric Brain Tumor Atlas is necessary to complete this work.
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.
- Arash Nabbi, PharmD, PhD - University Health Network
- Dr. Uri Tabori, MD - The Hospital for Sick Children
- Dr. Stefan Pfister, MD - Hopp-Children’s Cancer Center, Germany
- Dr. David Jones, PhD - Hopp-Children’s Cancer Center, Germany
- Dr. Jaeger, Hopp-Children’s Cancer Center, Germany
- Dr Katherine Hutchinson, PhD - Genentech
Trevor Pugh, PhD, FACMG
Cancer GenomicsClinical Molecular GeneticsBioinformaticsSoftware development
University of Toronto
Arash Nabbi, PhD
Uri Tabori, MD
The Tabori lab is focused on combining biological and translational research in paediatric oncology. Specifically, we are interested in studying mechanisms underlying brain tumor immortality and recurrence in the context of predisposition to cancer. Currently our group is studying 3 major areas rela
Stefan M. Pfister, MD
Our group aims to bridge the gap between generating genomic screening data as well as faithful models for preclinical drug testing, and exploiting these data for the sake of our patients.
Marcel Kool, PhD
Preclinical model systems, high-throughput drug screens, shRNA screens, and CRISPR/Cas9 screens, to find new and better drug targets and for understanding tumor development and primary and acquired therapy-related resistance mechanisms
Hopp Children's Cancer Center
David T.W. Jones, PhD
Our research in the area of HGG & DIPG aims at understanding the heterogeneity both within single tumors and between individuals, to identify the most important patterns of alterations in the cellular machinery. We then try to recapitulate these changes in model systems, in order to understand their
Natalie Jäger, PhD
With our analyses, we significantly support the INFORM program, an international project to create personalized molecular tumor profiles for children with recurrent or refractory tumors. By analyzing the tumor data, we identify molecular changes that may represent potential targets for a given drug
Katherine Hutchinson, PhD
Delineating Pediatric Glioma Progression Using Single-nuclei Sequencing
Low grade gliomas are the most prevalent brain cancer among children and deeper study is needed to steer treatment protocol for patients that experience recurrence. Using samples provided by the Children’s Brain Tumor Network, researchers hope to better understand this disease and to identify new therapies.